The inflammatory bowel disease treatment market is expected to register a CAGR of 2.5% during the forecast period. Inflammatory bowel disease is characterized by chronic inflammation of the digestive tract. It is an umbrella term for ulcerative colitis and Crohn’s disease. The market for inflammatory bowel disease treatment is growing worldwide due to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, increasing number of drugs in clinical trial and growing popularity of prebiotic and probiotic foods is likely to spur market growth. However, high capital investments required for drug discovery, unsatisfactory effectiveness of treatment, and stringent drug regulatory policies are restraining the growth of the inflammatory bowel disease treatment market.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6266
Market Segmentation The global inflammatory bowel disease treatment market has been segmented on the basis of drug class, disease indication, distribution channel, and end-user. Based on drug class, the market has been segmented into TNF inhibitors, aminosalicylates, immunomodulators, and corticosteroids. By disease indication, the market has been segmented into ulcerative colitis and Crohn’s disease. Based on distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. By end-user, the market has been segmented into hospitals and clinics and others. Based on region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has been further segmented into North America and South America. The European market has been further divided into Western Europe and Eastern Europe. Regional Market Summary Americas is expected to be the largest inflammatory bowel disease treatment market, by region. The increasing prevalence of anxiety and gluten allergies and inclination towards junk food has led to the increasing number of patients suffering from inflammatory bowel disease in the region. According to the Anxiety and Depression Association of America, anxiety was the most diagnosed mental disorder in the US, with around 40 million people, aged over 14, affected by anxiety every year. As per the Centers for Disease Control and Prevention (CDC), about 1.3% of US adults, approximately 3 million, were diagnosed with IBD, either Crohn’s disease or ulcerative colitis, in 2015. Furthermore, rising health awareness, the presence of key players, and established healthcare infrastructure are likely to enhance the growth of the inflammatory bowel disease treatment market in the region. According to the Centers for Medicare and Medicaid Services (CMS) in 2016, healthcare spending in the US increased by 4.3% to reach USD 3.3 trillion. Thus, increasing per capita income and rising healthcare spending will aid market growth in the Americas. Europe was the second-largest inflammatory bowel disease treatment market, by region in 2017. The European market is expected to exhibit steady growth during the forecast period owing to the increasing prevalence of inflammatory bowel disease, rising rate of alcohol abuse, unhealthy lifestyle habits, and the increasing incidence of anxiety and depression among adults. Additionally, factors such as increasing government initiatives and funding for research, the development of advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of the inflammatory bowel disease treatment market in Europe. Asia-Pacific is expected to be the fastest-growing inflammatory bowel disease treatment market with an exponential rise in patient population. Japan and China are expected to be the largest markets for inflammatory bowel disease treatment in Asia-Pacific. The rising prevalence of anxiety and depression among adults as well as the increasing abuse of alcohol and sedentary lifestyles are expected to result in a growing patient pool, fueling the demand for treatment drugs. Furthermore, comparatively lenient drug regulatory policies and increasing government initiatives for healthcare reform are expected to propel market growth during the forecast period. Rising healthcare expenditure and rising standards of living in the region are also driving the growth of the inflammatory bowel disease treatment market in Asia-Pacific. The market in the Middle East & Africa is expected to show the least growth due to a lack of awareness about the disease, limited access to and availability of treatment facilities, and lower prevalence of the disorder. However, the market may grow in the UAE, Kuwait, and Saudi Arabia. Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/inflammatory-bowel-disease-treatment-market-6266
Comentarios